Organization
Zhou Fangjian
1 clinical trial
Clinical trial
A Multicenter Randomized Controlled Clinical Study of Neoadjuvant Combination of Axitinib Plus PD-1 Monoclonal Antibody to Improve Disease Free Survival of Patients With Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-07-16